Also, a statistically significant prolongation of the time to progression from 0.9 to 2.3 months (log-rank p < 0.0002) and a statistically significant prolongation of median survival from 4.4 to 5.7 months (log-rank p < 0.0024) was observed in patients treated with gemcitabine compared to patients treated with 5-fluorouracil.